Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
rare diseases
Biotech
Amgen disappears lung disease program after phase 2 fail
Amgen is discontinuing a lung disease program after its investigational small molecule failed to hit any primary or secondary endpoints.
Gabrielle Masson
Oct 30, 2024 5:59pm
GemVax's peptide drug fails phase 2a neurodegenerative trial
Oct 29, 2024 11:28am
After agony, FDA adcomm favors Stealth's ultra-rare disease drug
Oct 10, 2024 6:20pm
GEMMABio gene therapy heads to Brazil with $100M government deal
Oct 8, 2024 1:43pm
PTC bounces back with positive data on FA prospect vatiquinone
Oct 8, 2024 9:34am
Jim Wilson's Franklin Biolabs launches with genetic med services
Oct 3, 2024 2:05pm
